carmofur has been researched along with Local Neoplasm Recurrence in 18 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The direct effect and safety of carmofur (Mifurol) in cases of advanced and recurrent breast cancer were evaluated as a cooperative study at twenty-two facilities nationwide." | 9.08 | [Clinical effects of carmofur (Mifurol) on advanced and recurrent breast cancer in a cooperative study. Research association for re-evaluation of direct effects of Mifurol on breast cancer]. ( Abe, R; Enomoto, K; Koyama, H; Kusama, M; Nishi, T; Sonoo, H; Takashima, S; Tominaga, T; Yamaguchi, S; Yoshida, M, 1995) |
| "To evaluate the effect of 1-hexylcarbamoyl-5-fluorouracil (HCFU), a derivative of 5-fluorouracil (5-FU), in preventing postoperative recurrence of bladder cancer, a randomized controlled study with 1-(2-tetrahydrofuryl)-5-fluorouracil (Tegafur) as the reference standard was performed." | 9.05 | [A randomized controlled study to compare 1-hexylcarbamoyl-5-fluorouracil (HCFU) and 1-(2-tetrahydrofuryl)-5-fluorouracil (Tegafur) for the prevention of post-operative recurrence of bladder cancer]. ( Hisazumi, H; Kanda, S; Katsumi, T; Kawaguchi, K; Mikawa, I; Misaki, T; Miyagi, T; Nakamura, T; Orito, M; Sakai, A, 1985) |
| "This study was carried out to evaluate the effects of carmofur (Mifurol), a masked compound of 5-fluorouracil (5-FU), in preventing postoperative recurrence of urogenital carcinoma (especially in bladder cancer)." | 7.67 | [Study on effectiveness of carmofur (Mifurol) in urogenital carcinoma, especially bladder cancer, as a post-operative adjuvant chemotherapeutic agent]. ( Funai, K; Hayahara, N; Kawakita, J; Kishimoto, T; Maekawa, M; Morikawa, Y; Nishijima, T; Nishio, S; Yasumoto, R; Yuki, K, 1987) |
| "To treat superficial bladder cancer or invasive bladder cancer presenting as a solitary tumor, conservative therapy such as transurethral resection of bladder tumor or partial cystectomy has long been carried out." | 5.28 | [Study of preventive effect of 1-hexylcarbamoyl-5-fluorouracil (HCFU) or combination of HCFU and 2.5-di-O-acetyl-D-glucaro (1-4) (6-3) dilactone (SLA) after preservative operation against bladder cancer]. ( Hayahara, N; Horii, A; Kashihara, N; Kawakita, J; Kishimoto, T; Maekawa, M; Morikawa, Y; Nishijima, T; Wada, S; Yasumoto, R, 1992) |
| "The direct effect and safety of carmofur (Mifurol) in cases of advanced and recurrent breast cancer were evaluated as a cooperative study at twenty-two facilities nationwide." | 5.08 | [Clinical effects of carmofur (Mifurol) on advanced and recurrent breast cancer in a cooperative study. Research association for re-evaluation of direct effects of Mifurol on breast cancer]. ( Abe, R; Enomoto, K; Koyama, H; Kusama, M; Nishi, T; Sonoo, H; Takashima, S; Tominaga, T; Yamaguchi, S; Yoshida, M, 1995) |
| "To evaluate the effect of 1-hexylcarbamoyl-5-fluorouracil (HCFU), a derivative of 5-fluorouracil (5-FU), in preventing postoperative recurrence of bladder cancer, a randomized controlled study with 1-(2-tetrahydrofuryl)-5-fluorouracil (Tegafur) as the reference standard was performed." | 5.05 | [A randomized controlled study to compare 1-hexylcarbamoyl-5-fluorouracil (HCFU) and 1-(2-tetrahydrofuryl)-5-fluorouracil (Tegafur) for the prevention of post-operative recurrence of bladder cancer]. ( Hisazumi, H; Kanda, S; Katsumi, T; Kawaguchi, K; Mikawa, I; Misaki, T; Miyagi, T; Nakamura, T; Orito, M; Sakai, A, 1985) |
| "This study was carried out to evaluate the effects of carmofur (Mifurol), a masked compound of 5-fluorouracil (5-FU), in preventing postoperative recurrence of urogenital carcinoma (especially in bladder cancer)." | 3.67 | [Study on effectiveness of carmofur (Mifurol) in urogenital carcinoma, especially bladder cancer, as a post-operative adjuvant chemotherapeutic agent]. ( Funai, K; Hayahara, N; Kawakita, J; Kishimoto, T; Maekawa, M; Morikawa, Y; Nishijima, T; Nishio, S; Yasumoto, R; Yuki, K, 1987) |
| "Adjuvant therapy of colorectal cancer with oral fluorinated pyrimidines is attractive because of its ease of administration and good tolerability." | 2.42 | Efficacy of oral adjuvant therapy after resection of colorectal cancer: 5-year results from three randomized trials. ( Burzykowski, T; Buyse, M; Hamada, C; Ohashi, Y; Piedbois, P; Sakamoto, J, 2004) |
| "Of them, 315 node-negative stage II colorectal cancer cases were enrolled." | 1.43 | Micrometastasis Volume in Lymph Nodes Determines Disease Recurrence Rate of Stage II Colorectal Cancer: A Prospective Multicenter Trial. ( Doki, Y; Fukunaga, M; Ikeda, M; Kato, T; Matsuura, N; Miyake, Y; Mizushima, T; Monden, M; Mori, M; Murata, K; Nakamura, Y; Nezu, R; Noura, S; Ohnishi, T; Ohtsuka, M; Ohue, M; Sekimoto, M; Takemasa, I; Yamamoto, H, 2016) |
| " After right lobectomy of the liver which contained the tumors of S6 2 cm and S8 3 cm in diameter 7 months before, the patient was treated with hepatic arterial embolization (TAE) combined with infusion of anti-cancer drug (ADM, CDDP) four times since June 1990." | 1.28 | [A case report of postoperative recurrent hepatocellular carcinoma effectively treated with HCFU administration combined with TAE]. ( Imai, Y; Ito, J; Kobayashi, K; Okamoto, M; Tagawa, K; Taniguchi, M; Tanzawa, Y; Toda, N; Unuma, T; Uta, Y, 1992) |
| "To treat superficial bladder cancer or invasive bladder cancer presenting as a solitary tumor, conservative therapy such as transurethral resection of bladder tumor or partial cystectomy has long been carried out." | 1.28 | [Study of preventive effect of 1-hexylcarbamoyl-5-fluorouracil (HCFU) or combination of HCFU and 2.5-di-O-acetyl-D-glucaro (1-4) (6-3) dilactone (SLA) after preservative operation against bladder cancer]. ( Hayahara, N; Horii, A; Kashihara, N; Kawakita, J; Kishimoto, T; Maekawa, M; Morikawa, Y; Nishijima, T; Wada, S; Yasumoto, R, 1992) |
| "A 51-year-old man with recurrent gastric cancer was treated by combined administration of Cisplatin and Carmofur." | 1.27 | [A case of recurrent gastric cancer successfully treated with a combination of cisplatin and carmofur]. ( Abe, S; Akazawa, S; Fujiki, T; Futatsuki, K; Kanda, Y; Kuwatsuru, R; Saifuku, K; Yamamoto, K; Yoon, S; Yoshida, K, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (27.78) | 18.7374 |
| 1990's | 9 (50.00) | 18.2507 |
| 2000's | 3 (16.67) | 29.6817 |
| 2010's | 1 (5.56) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yamamoto, H | 1 |
| Murata, K | 1 |
| Fukunaga, M | 1 |
| Ohnishi, T | 1 |
| Noura, S | 1 |
| Miyake, Y | 1 |
| Kato, T | 1 |
| Ohtsuka, M | 1 |
| Nakamura, Y | 1 |
| Takemasa, I | 1 |
| Mizushima, T | 1 |
| Ikeda, M | 2 |
| Ohue, M | 1 |
| Sekimoto, M | 1 |
| Nezu, R | 1 |
| Matsuura, N | 1 |
| Monden, M | 1 |
| Doki, Y | 1 |
| Mori, M | 1 |
| Sakamoto, J | 2 |
| Ohashi, Y | 2 |
| Hamada, C | 2 |
| Buyse, M | 1 |
| Burzykowski, T | 1 |
| Piedbois, P | 1 |
| Rahman, M | 1 |
| Kodaira, S | 1 |
| Ito, K | 1 |
| Nakazato, H | 1 |
| Yasutomi, M | 1 |
| Kusama, M | 1 |
| Tominaga, T | 1 |
| Enomoto, K | 1 |
| Yoshida, M | 1 |
| Koyama, H | 1 |
| Sonoo, H | 1 |
| Takashima, S | 1 |
| Abe, R | 1 |
| Nishi, T | 1 |
| Yamaguchi, S | 1 |
| Teshima, K | 1 |
| Noda, K | 1 |
| Yamagata, S | 1 |
| Sugawa, T | 1 |
| Okamura, S | 1 |
| Kubo, H | 1 |
| Sugimoto, O | 1 |
| Nakajima, H | 1 |
| Yamabe, T | 1 |
| Katsumata, K | 1 |
| Yamashita, S | 1 |
| Hoshino, S | 1 |
| Tani, C | 1 |
| Yamamoto, K | 2 |
| Kimura, K | 1 |
| Yamamoto, M | 1 |
| Arii, S | 1 |
| Sugahara, K | 1 |
| Tobe, T | 1 |
| Ono, T | 2 |
| Nagasue, N | 2 |
| Kohno, H | 2 |
| Hayashi, T | 1 |
| Uchida, M | 1 |
| Yukaya, H | 1 |
| Yamanoi, A | 2 |
| Nazmy El Assal, O | 1 |
| Imai, Y | 1 |
| Ito, J | 1 |
| Tanzawa, Y | 1 |
| Toda, N | 1 |
| Okamoto, M | 1 |
| Kobayashi, K | 1 |
| Taniguchi, M | 1 |
| Uta, Y | 1 |
| Tagawa, K | 1 |
| Unuma, T | 1 |
| Okuyama, K | 1 |
| Awano, T | 1 |
| Tohnosu, N | 1 |
| Koide, Y | 1 |
| Matsubara, H | 1 |
| Nakaichi, H | 1 |
| Funami, Y | 1 |
| Matsushita, K | 1 |
| Amano, H | 1 |
| Ochiai, T | 1 |
| Wada, S | 1 |
| Yasumoto, R | 2 |
| Kashihara, N | 1 |
| Kishimoto, T | 2 |
| Maekawa, M | 2 |
| Hayahara, N | 2 |
| Kawakita, J | 2 |
| Nishijima, T | 2 |
| Morikawa, Y | 2 |
| Horii, A | 1 |
| Moriya, Y | 1 |
| Sugihara, K | 1 |
| Hojo, K | 1 |
| Makuuchi, M | 1 |
| Sawada, M | 2 |
| Nishio, S | 1 |
| Funai, K | 1 |
| Yuki, K | 1 |
| Ozaki, M | 1 |
| Hongo, J | 1 |
| Hirota, Y | 1 |
| Inagaki, M | 1 |
| Kuwatsuru, R | 1 |
| Akazawa, S | 1 |
| Yoon, S | 1 |
| Yoshida, K | 1 |
| Saifuku, K | 1 |
| Abe, S | 1 |
| Fujiki, T | 1 |
| Kanda, Y | 1 |
| Futatsuki, K | 1 |
| Misaki, T | 1 |
| Hisazumi, H | 1 |
| Sakai, A | 1 |
| Nakamura, T | 1 |
| Kanda, S | 1 |
| Mikawa, I | 1 |
| Miyagi, T | 1 |
| Katsumi, T | 1 |
| Orito, M | 1 |
| Kawaguchi, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety of Donafenib Combined With TACE as Adjuvant Therapy of Patients With Hepatocellular Carcinoma at a High Risk of Recurrence After Radical Resection[NCT05161143] | Phase 2 | 30 participants (Anticipated) | Interventional | 2021-12-31 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for carmofur and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Efficacy of oral adjuvant therapy after resection of colorectal cancer: 5-year results from three randomized trials.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2004 |
An individual patient data meta-analysis of adjuvant therapy with carmofur in patients with curatively resected colon cancer.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Colonic Neoplasms; Digestive System Surgical Procedur | 2005 |
Adjuvant chemotherapy after resection of hepatocellular carcinoma causes deterioration of long-term prognosis in cirrhotic patients: metaanalysis of three randomized controlled trials.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Hepa | 2001 |
5 trials available for carmofur and Local Neoplasm Recurrence
| Article | Year |
|---|---|
[Clinical effects of carmofur (Mifurol) on advanced and recurrent breast cancer in a cooperative study. Research association for re-evaluation of direct effects of Mifurol on breast cancer].
Topics: Administration, Oral; Adult; Aged; Anorexia; Antineoplastic Agents; Breast Neoplasms; Dizziness; Dru | 1995 |
[Long-term administration of carmofur as a post-operative adjuvant chemotherapy for cervical adenocarcinoma. Cervical Adenocarcinoma Cooperative Research Association].
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; | 1994 |
Adjuvant oral chemotherapy to prevent recurrence after curative resection for hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease-Free Survival; Flu | 1996 |
Adjuvant chemotherapy with epirubicin and carmofur after radical resection of hepatocellular carcinoma: a prospective randomized study.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellul | 1997 |
[A randomized controlled study to compare 1-hexylcarbamoyl-5-fluorouracil (HCFU) and 1-(2-tetrahydrofuryl)-5-fluorouracil (Tegafur) for the prevention of post-operative recurrence of bladder cancer].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Clinical Trials as Topic; Drug Administrat | 1985 |
10 other studies available for carmofur and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Micrometastasis Volume in Lymph Nodes Determines Disease Recurrence Rate of Stage II Colorectal Cancer: A Prospective Multicenter Trial.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoembryonic Antigen; Colorectal Neoplasms; Dise | 2016 |
[Evaluation of neoadjuvant combination chemotherapy with pirarubicin, carmofur and tamoxifen citrate on outpatients with advanced and recurrence breast cancer].
Topics: Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherap | 1994 |
[A case report of postoperative recurrent hepatocellular carcinoma effectively treated with HCFU administration combined with TAE].
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Embolization, Therapeut | 1992 |
[Signification of liver metastases of colorectal cancer with special reference to recurrence in the residual liver after hepatic resection].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Doxorubi | 1992 |
[Study of preventive effect of 1-hexylcarbamoyl-5-fluorouracil (HCFU) or combination of HCFU and 2.5-di-O-acetyl-D-glucaro (1-4) (6-3) dilactone (SLA) after preservative operation against bladder cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitio | 1992 |
Adjuvant hepatic intra-arterial chemotherapy after potentially curative hepatectomy for liver metastases from colorectal cancer: a pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 1991 |
[Experimental chemotherapy of ovarian cancers heterotransplanted in nude mice].
Topics: Adenocarcinoma, Mucinous; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 1985 |
[Study on effectiveness of carmofur (Mifurol) in urogenital carcinoma, especially bladder cancer, as a post-operative adjuvant chemotherapeutic agent].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Combined Modality Thera | 1987 |
[Effect of post operative maintenance chemotherapy against ovarian cancer].
Topics: Animals; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Humans; Mice; Mice, | 1987 |
[A case of recurrent gastric cancer successfully treated with a combination of cisplatin and carmofur].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administrat | 1987 |